Clinical trial

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

NCT00123643

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record rosiglitazone Normalized identity: rosiglitazoneView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record glyburide Normalized identity: glyburideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-05-01

PhasePHASE4

Conditions

Type 2 Diabetes Mellitusverified · MONDO: type 2 diabetes mellitus

Interventions

rosiglitazoneDRUG · verified · RxNorm: rosiglitazone

glyburideDRUG · verified · RxNorm: glyburide

Sponsors & collaborators

St. Paul Heart Cliniclead sponsor

GlaxoSmithKlinecollaborator

Mapped research locations

Saint PaulMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00123643 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.